Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study

Jeanette K. Doorduijn; Gustaaf W. van Imhoff; Bronno van der Holt; Harry C. Schouten; Martijn R. Schaafsma; Marius A. MacKenzie; Joke W. Baars; Marie Jose Kersten; Pieternella J. Lugtenburg; Martin J. van den Bent; Roelien H. Enting; Fokje M. Spoelstra; Philip Poortmans; Jacoline E. C. Bromberg

doi:10.1002/hon.2342

Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study

Jeanette K. Doorduijn^*, Gustaaf W. van Imhoff, Bronno van der Holt, Harry C. Schouten, Martijn R. Schaafsma, Marius A. MacKenzie, Joke W. Baars, Marie Jose Kersten, Pieternella J. Lugtenburg, Martin J. van den Bent, Roelien H. Enting, Fokje M. Spoelstra, Philip Poortmans, Jacoline E. C. Bromberg

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	497-503
Number of pages	7
Journal	Hematological Oncology
Volume	35
Issue number	4
DOIs	https://doi.org/10.1002/hon.2342
Publication status	Published - Dec 2017

Keywords

clinical trial
methotrexate
rituximab
secondary CNS lymphoma
transplantation
treatment
NON-HODGKINS-LYMPHOMA
PRIMARY CNS LYMPHOMA
MABTHERA INTERNATIONAL TRIAL
CHEMOTHERAPY PLUS RITUXIMAB
STUDY-GROUP DSHNHL
AGGRESSIVE LYMPHOMA
ELDERLY-PATIENTS
MARROW-TRANSPLANTATION
INTRAOCULAR LYMPHOMA
RESPONSE CRITERIA

Access to Document

10.1002/hon.2342

Cite this

Doorduijn, J. K., van Imhoff, G. W., van der Holt, B., Schouten, H. C., Schaafsma, M. R., MacKenzie, M. A., Baars, J. W., Kersten, M. J., Lugtenburg, P. J., van den Bent, M. J., Enting, R. H., Spoelstra, F. M., Poortmans, P., & Bromberg, J. E. C. (2017). Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study. Hematological Oncology, 35(4), 497-503. https://doi.org/10.1002/hon.2342

Doorduijn, Jeanette K. ; van Imhoff, Gustaaf W. ; van der Holt, Bronno ; Schouten, Harry C. ; Schaafsma, Martijn R. ; MacKenzie, Marius A. ; Baars, Joke W. ; Kersten, Marie Jose ; Lugtenburg, Pieternella J. ; van den Bent, Martin J. ; Enting, Roelien H. ; Spoelstra, Fokje M. ; Poortmans, Philip ; Bromberg, Jacoline E. C. / Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation : results of the HOVON 80 phase 2 study. In: Hematological Oncology. 2017 ; Vol. 35, No. 4. pp. 497-503.

@article{522efa00978f432b88027cdc115a60c7,

title = "Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study",

keywords = "clinical trial, methotrexate, rituximab, secondary CNS lymphoma, transplantation, treatment, NON-HODGKINS-LYMPHOMA, PRIMARY CNS LYMPHOMA, MABTHERA INTERNATIONAL TRIAL, CHEMOTHERAPY PLUS RITUXIMAB, STUDY-GROUP DSHNHL, AGGRESSIVE LYMPHOMA, ELDERLY-PATIENTS, MARROW-TRANSPLANTATION, INTRAOCULAR LYMPHOMA, RESPONSE CRITERIA",

author = "Doorduijn, {Jeanette K.} and {van Imhoff}, {Gustaaf W.} and {van der Holt}, Bronno and Schouten, {Harry C.} and Schaafsma, {Martijn R.} and MacKenzie, {Marius A.} and Baars, {Joke W.} and Kersten, {Marie Jose} and Lugtenburg, {Pieternella J.} and {van den Bent}, {Martin J.} and Enting, {Roelien H.} and Spoelstra, {Fokje M.} and Philip Poortmans and Bromberg, {Jacoline E. C.}",

year = "2017",

month = dec,

doi = "10.1002/hon.2342",

language = "English",

volume = "35",

pages = "497--503",

journal = "Hematological Oncology",

issn = "0278-0232",

publisher = "Wiley",

number = "4",

}

Doorduijn, JK, van Imhoff, GW, van der Holt, B, Schouten, HC, Schaafsma, MR, MacKenzie, MA, Baars, JW, Kersten, MJ, Lugtenburg, PJ, van den Bent, MJ, Enting, RH, Spoelstra, FM, Poortmans, P & Bromberg, JEC 2017, 'Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study', Hematological Oncology, vol. 35, no. 4, pp. 497-503. https://doi.org/10.1002/hon.2342

Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation : results of the HOVON 80 phase 2 study. / Doorduijn, Jeanette K.; van Imhoff, Gustaaf W.; van der Holt, Bronno; Schouten, Harry C.; Schaafsma, Martijn R.; MacKenzie, Marius A.; Baars, Joke W.; Kersten, Marie Jose; Lugtenburg, Pieternella J.; van den Bent, Martin J.; Enting, Roelien H.; Spoelstra, Fokje M.; Poortmans, Philip; Bromberg, Jacoline E. C.

In: Hematological Oncology, Vol. 35, No. 4, 12.2017, p. 497-503.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation

T2 - results of the HOVON 80 phase 2 study

AU - Doorduijn, Jeanette K.

AU - van Imhoff, Gustaaf W.

AU - van der Holt, Bronno

AU - Schouten, Harry C.

AU - Schaafsma, Martijn R.

AU - MacKenzie, Marius A.

AU - Baars, Joke W.

AU - Kersten, Marie Jose

AU - Lugtenburg, Pieternella J.

AU - van den Bent, Martin J.

AU - Enting, Roelien H.

AU - Spoelstra, Fokje M.

AU - Poortmans, Philip

AU - Bromberg, Jacoline E. C.

PY - 2017/12

Y1 - 2017/12

KW - clinical trial

KW - methotrexate

KW - rituximab

KW - secondary CNS lymphoma

KW - transplantation

KW - treatment

KW - NON-HODGKINS-LYMPHOMA

KW - PRIMARY CNS LYMPHOMA

KW - MABTHERA INTERNATIONAL TRIAL

KW - CHEMOTHERAPY PLUS RITUXIMAB

KW - STUDY-GROUP DSHNHL

KW - AGGRESSIVE LYMPHOMA

KW - ELDERLY-PATIENTS

KW - MARROW-TRANSPLANTATION

KW - INTRAOCULAR LYMPHOMA

KW - RESPONSE CRITERIA

U2 - 10.1002/hon.2342

DO - 10.1002/hon.2342

M3 - Article

VL - 35

SP - 497

EP - 503

JO - Hematological Oncology

JF - Hematological Oncology

SN - 0278-0232

IS - 4

ER -

Doorduijn JK, van Imhoff GW, van der Holt B, Schouten HC, Schaafsma MR, MacKenzie MA et al. Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study. Hematological Oncology. 2017 Dec;35(4):497-503. https://doi.org/10.1002/hon.2342